NCT05413343
Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
Registry fields
- Overall status
- COMPLETED
- Conditions
- Severe Sepsis, Carbapenem Resistant Bacterial Infection
- Study type
- OBSERVATIONAL
- Intervention type
- DRUG
- Interventions
- Ceftazidime-avibactam
- Lead sponsor
- First Affiliated Hospital of Zhejiang University (OTHER)
Cached at: 2026-09-10 23:27:16
Brief summary
This prospective observational study is conducted at the First Affiliated Hospital of Zhejiang University School of Medicine from June 1, 2021 to January 1, 2024. The study aims to characterize the population pharmacokinetics of ceftazidime (CAZ) and avibactam (AVI) in critically ill patients receiving ceftazidime-avibactam (CAZ-AVI), including patients with and without renal replacement therapy (RRT). Plasma concentrations of CAZ and AVI will be measured after the first-dose and steady-state administrations. Population pharmacokinetic and pharmacokinetic/pharmacodynamic target-attainment analyses will be performed to explore dosing strategies according to renal function and RRT status.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue